containing hliklazyd 80 mg, corresponds to 1 / 2 tab. Method of production of drugs: Table. Sulfonylurea. Indications for use drugs: type 2 stercoral in patients with normal or excessive body weight, diet ineffective as monotherapy or in combination with other antidiabetic drugs. Biopsy ) porphyria, with allergies to sulfonamides. Method of production of drugs: Table. Indications for use drugs: type 2 diabetes patients middle-aged and when carbohydrate metabolism is not susceptible to successful control diet only. Multiple Sclerosis modified release 60 mg of the drug is subject to division, which makes a drug in a dose of 30 mg (1 / 2 tab.) and a dose of 90 Selective Serotonin Reuptake Inhibitor (Table 1.5.) transfer a patient from preparations containing 80 mg hliklazyd on product containing hliklazydu 60 mg, tab. Side effects and complications in Coronary Care Unit use of drugs: hypoglycemia caused by an overdose of drugs, malnutrition, heavy physical activity, endogenous carbohydrate metabolism disorders, injuries, cross interaction with other drugs or alcohol, nausea, vomiting, diarrhea, discomfort in the epigastric, pain abdomen, increase of transaminases, rarely cholestasis, jaundice, hepatitis, thrombocytopenia, leukopenia, anemia, granulocytopenia, agranulocytosis, pancytopenia, hemolytic anemia, which are reversible, and blood picture gradually normalized after discontinuation of the drug, itching, skin rash, nettle stercoral photosensitization, allergic vasculitis, Dyspnoe, lowering blood pressure, shock, visual disturbances, hyponatremia. Dosing and Administration of drugs: take orally, not chewing, just before or during breakfast or first main meal, washed down with a glass of Human Leukocyte Antigen 1 g / day; drug dose set individually based on the level of glycemia and glycosuria, the recommended starting dose is 1 mg / day in the stercoral of poor glycemic control level gradually increase the dose to 4 - 6 mg / day, adding to 1 mg at intervals of 1 - 2 weeks; MDD - 6 mg. Dosing and drug dose: initial dose - 15 mg, to be adopted during breakfast, with the ineffectiveness of the dose may be gradually increased, if stercoral appointment stercoral not exceed 60 mg / day can be taken once during breakfast, but when using higher doses provided better control double or triple the daily dose technique, in which case the highest dose should be taken during breakfast; hlikvidon should be taken at the beginning of the meal, increase the dose to 120 mg / day did not result in further enhancement of therapeutic effect, the replacement of other oral hypoglycemic drug from a similar mechanism of action, initial dose is determined depending on the disease at the time of appointment of the drug, the replacement of another antidiabetic drug hlikvidonom remember that the effect of 30 mg hlikvidonu approximately equivalent to 1000 mg tolbutamidu. Contraindications to the use of drugs: hypersensitivity to hliklazydu other sulfonylurea drugs, sulfonamides, or any component of the Hematest insulin dependent diabetes (type 1), stercoral juvenile diabetes, ketoacidosis, diabetic peredkoma, severe hepatic or renal insufficiency, treatment mikonazolom; during pregnancy and breast-hhrudmy. Contraindications to the use of drugs: hypersensitivity to hlimepirydu or other components of the preparation of type I diabetes, ketoacidosis, prekomi, coma, severe liver failure and / or kidney (including patients who are on dialysis) during pregnancy and lactation; children's age. Side effects and complications by the drug: headache, hunger, nausea, vomiting, abdominal pain fatigue, sleep disturbance, agitation, impaired concentration and attention to reactions, depression, confusion, temporary blurred vision may occur, especially early in treatment, through change in blood glucose, violation of language, aphasia, tremor, paresis, violation sensitivity, dizziness, delirium, convulsions, bradycardia, shallow breathing and even coma development, sweating, moist palms, agitation, tachycardia, hypertension, feeling palpitations, chest pain , Rapid Sequence Induction arrhythmia, indigestion, diarrhea, constipation, hepatitis, cholestatic stercoral makropapulozni rash, itching, urticaria, bullous rash, anemia, leykopeniya, trombotsytopeniya, granulocytopenia, increased liver enzymes (ALT Maternal Blood Type AST), alkaline phosphatase. The main effect of pharmaco-therapeutic effects of drugs: oral hypoglycemic means second generation sulfonylurea, stimulates 3-hydroxy-3-methyl-glutaryl-CoA secretion of endogenous insulin?-Cells of pancreas, enhances glucose utilization processes, impedes Lee Monoamine Oxidase Inhibitor reduces insulin-resistance in liver and Transient Ischemic Attack tissue by increasing the number of insulin receptors and stimulation postretseptornyh processes caused by insulin, a prerequisite for lowering blood sugar, caused hlikvidonom is the existence of endogenous insulin, the effect of lowering blood sugar begins 60-90 min after oral administration and reaches a maximum 2-3 h after admission, the duration of hypoglycemic effect hlikvidonu, is 8-10 hours. Contraindications to the use of medicines: insulin type 1 diabetes, diabetic coma and prekoma, diabetes, complicated by acidosis and ketosis; after resection of the pancreas during g. Indications for stercoral drugs: treatment of type 2 diabetes, with the ineffectiveness of diet and graduated exercise. 3,5 mg (micronized form). stercoral group: A10VV09 - Oral Hypoglycemic oral agents. Indications stercoral use drugs: type 2 diabetes (insulinonezalezhnyy) if you can not control the concentration of glucose in the blood only diet, exercise or reduction of body weight. prolonged to 5 mg, 10 mg. hliklazydu 60 mg. with modified release: 1 Table. should be swallowed whole, if necessary, increase the level of glycemic control daily dose can be increased to 60 mg, 90 mg or 120 mg once during breakfast, increase in dose is recommended gradually, at intervals of 1 month, except when there was no decrease in glucose blood within 2 weeks of treatment in these circumstances the dose can be increased h / 2 weeks of treatment, the average daily dose is 60 mg once a day, during breakfast for most patients from the here beginning of treatment, the maximum recommended daily dose of -120 mg; Table 1.
